Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.60 |
| ▸ | FLT3 | P36888 | 4/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | FLT1 | P17948 | 2/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | FLT4 | P35916 | 2/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19816 | 0.90 | RET (1.00) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL19817 | 0.90 | RET (1.00) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL17480337 | 0.85 | KDR (0.80) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL17480306 | 0.84 | RET (0.72) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL8199244 | 0.81 | CHEK1 (0.70) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL8199248 | 0.81 | CHEK1 (0.70) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL17480314 | 0.78 | RET (0.77) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL17480347 | 0.78 | RET (0.68) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL17480315 | 0.77 | RET (0.72) | RETPDGFRBALKFLT3KDR | |
| SCHEMBL17480292 | 0.77 | RET (0.78) | RETPDGFRBALKFLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | RET 348/4885PDGFRB 572/4885ALK 1316/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | RET 107/4885PDGFRB 495/4885ALK 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.